Free US stock ESG scoring and sustainability analysis for responsible investing considerations. We evaluate environmental, social, and governance factors that increasingly impact long-term company performance.
This analysis covers the April 24, 2026 announcement that Bristol Myers Squibb (NYSE: BMY) and co-marketing partner Pfizer (NYSE: PFE) will list their top-selling anticoagulant Eliquis on the Mark Cuban Cost Plus Drug Company (MCCPDC) platform starting the following week, priced at $345 for a 30-day
Bristol Myers Squibb (BMY) - Partners With Pfizer to List Blockbuster Anticoagulant Eliquis on Mark Cuban Cost Plus Platform at $345 Monthly - Bond Issuance
BMY - Stock Analysis
4354 Comments
719 Likes
1
Learah
Senior Contributor
2 hours ago
Highlights the nuances of market momentum effectively.
๐ 266
Reply
2
Aarn
Engaged Reader
5 hours ago
Well-rounded analysis โ easy to follow and understand.
๐ 136
Reply
3
Jabal
Returning User
1 day ago
Let me find my people real quick.
๐ 285
Reply
4
Arif
Experienced Member
1 day ago
Free US stock cash flow analysis and free cash flow yield calculations to identify companies returning value to shareholders. Our cash flow research helps you find companies with the financial flexibility to grow and return capital.
๐ 112
Reply
5
Zofie
Consistent User
2 days ago
This unlocked a memory I never had.
๐ 149
Reply
© 2026 Market Analysis. All data is for informational purposes only.